AB Science granted European patent for masitinib in treating sickle cell disease until 2040
Our lead product, masitinib, is a tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through more than 20 indications in oncology, inflammatory diseases, and central nervous system diseases. AB Science has its headquarters in Paris and is listed on Euronext Paris (ticker: AB). For more information, please visit our website: … Read more